Gold prices bounce off 3-week lows; demand likely longer term
Amicus Therapeutics (NASDAQ:FOLD) stock reached a 52-week low, trading at 5.79 USD. This marks a significant downturn for the company, which has experienced a 40.48% decrease in its stock value over the past year. Despite the decline, the company maintains impressive gross profit margins of 90.6% and strong liquidity with a current ratio of 3.34. According to InvestingPro analysis, the stock appears slightly undervalued at current levels. The decline reflects a challenging period for Amicus Therapeutics as investors react to market dynamics and company-specific developments. The 52-week low underscores the volatility and pressures facing the biotech sector, highlighting the importance of strategic adjustments and investor confidence in shaping future performance. Revenue growth remains robust at 28.25%, and InvestingPro data reveals 12 additional key insights about the company’s financial health and future prospects.
In other recent news, Amicus Therapeutics reported first-quarter 2025 earnings that exceeded analyst expectations, with adjusted earnings per share of $0.03 compared to the anticipated -$0.02. However, the company’s revenue of $125.25 million fell short of Wall Street’s forecast of $136.65 million. Despite the revenue miss, Amicus saw a 15% year-over-year increase in total revenue at constant exchange rates, driven by a 6% rise in Galafold sales to $104.2 million and a 92% surge in Pombiliti + Opfolda sales to $21.0 million. The company adjusted its 2025 total revenue growth guidance to 15-22%, down from a previous outlook of 17-24%. Amicus maintained its Galafold revenue growth guidance of 10-15% but lowered expectations for Pombiliti + Opfolda growth to 50-65% from 65-85%. The company reiterated its aim to achieve GAAP profitability in the second half of 2025 and ended the quarter with $250.6 million in cash and marketable securities. Additionally, Amicus announced it has licensed U.S. commercial rights to Dimerix’s DMX-200, a Phase 3 treatment for a rare kidney disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.